Suppr超能文献

显性负性Erk2的表达抑制AP-1反式激活和肿瘤转化。

Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.

作者信息

Watts R G, Huang C, Young M R, Li J J, Dong Z, Pennie W D, Colburn N H

机构信息

National Cancer Institute-FCRDC, Laboratory of Biochemical Physiology, Frederick, Maryland 21702-1201, USA.

出版信息

Oncogene. 1998 Dec 31;17(26):3493-8. doi: 10.1038/sj.onc.1202259.

Abstract

The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression or exposure to tumor promoters or to growth factors, and have been implicated in AP-1 transactivation in some models. We have shown that tumor promoter induced activation of the transcription factor AP-1 is required for induced neoplastic transformation in the Balb/C JB6 cell model. Jun and Fos family protein levels have been found not to be limiting for AP-1 response. The present study asks whether activation of Erks1 and 2 is required for AP-1 transactivation and transformation of JB6 cells and whether Erks might be targeted for cancer prevention. Expression of either of two different dominant negative kinase inactive Erk2 mutants in transformation sensitive (P+) JB6 cells substantially inhibited the tumor promoter induced activation of Erks1 and 2 and of AP-1 measured by a collagenase-luciferase reporter. Multiple mutant Erk2 expressing clonal lines were also rendered non-responsive to induced neoplastic transformation. These observations, together with our recent finding attributing AP-1 non-responsiveness to Erk deficiency in a clonal line of transformation resistant (P-) cells, argue for a requirement for Erks1 and/or 2 activation in AP-1 transactivation in the mouse JB6 neoplastic progression model, and suggest the utility of Erks as a prevention target.

摘要

丝裂原活化蛋白(MAP)激酶或细胞外信号调节激酶(Erks)可因Ras表达、暴露于肿瘤启动子或生长因子而被激活,在某些模型中与AP-1反式激活有关。我们已经表明,在Balb/C JB6细胞模型中,肿瘤启动子诱导的转录因子AP-1激活是诱导肿瘤转化所必需的。已发现Jun和Fos家族蛋白水平对AP-1反应没有限制作用。本研究探讨激活Erks1和2是否是AP-1反式激活和JB6细胞转化所必需的,以及Erks是否可作为癌症预防的靶点。在对转化敏感的(P+)JB6细胞中表达两种不同的显性负性激酶失活Erk2突变体中的任何一种,均可显著抑制肿瘤启动子诱导的Erks1和2以及通过胶原酶-荧光素酶报告基因检测的AP-1的激活。多个表达突变体Erk2的克隆系也对诱导的肿瘤转化无反应。这些观察结果,连同我们最近在一个转化抗性(P-)细胞克隆系中发现AP-1无反应归因于Erk缺乏,表明在小鼠JB6肿瘤进展模型中,AP-1反式激活需要激活Erks1和/或2,并提示Erks作为预防靶点的实用性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验